AstraZeneca and Eli Lilly’s Alzheimer’s treatment to be fast tracked

AstraZeneca and Eli Lilly have received US Food and Drug Administration (FDA) fast track designation for the development of a treatment for Alzheimer’s.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

PTAB grants inter partes review of China’s firm’s Alzheimer’s patent

22 July 2021 The US Patent Trial and Appeal Board has given the go-ahead for an inter partes review of a Chinese pharma company’s US patent related to a treatment for Alzheimer’s.

Americas

Eli Lilly’s Dermira accuses Perrigo of infringing patents

22 October 2020 Pharmaceutical company Eli Lilly’s subsidiary Dermira has accused generic drugmaker Perrigo of infringing eight patents for Qbrexza, a prescription-only cloth towelette approved to treat hyperhidrosis, a condition that causes excessive underarm sweating.

More on this story

Americas

PTAB grants inter partes review of China’s firm’s Alzheimer’s patent

22 July 2021 The US Patent Trial and Appeal Board has given the go-ahead for an inter partes review of a Chinese pharma company’s US patent related to a treatment for Alzheimer’s.

Americas

Eli Lilly’s Dermira accuses Perrigo of infringing patents

More on this story

Americas

PTAB grants inter partes review of China’s firm’s Alzheimer’s patent

22 July 2021 The US Patent Trial and Appeal Board has given the go-ahead for an inter partes review of a Chinese pharma company’s US patent related to a treatment for Alzheimer’s.

Americas

Eli Lilly’s Dermira accuses Perrigo of infringing patents